文章摘要
桂参通脉胶囊对心衰大鼠AngII、ALD的影响研究
Effect of Guishen Tongmai Capsule on AngII and ALD in Rats with Heart Failure
投稿时间:2019-10-11  录用日期:2019-10-28
DOI:
中文关键词: 桂参通脉胶囊  心力衰竭  AngII  ALD
英文关键词: Guishen Tongmai Capsule  Heart Failure  AngII  ALD.
基金项目:西安市科技计局立项课题《中医临床技术及临床用药的疗效研究—桂参通脉胶囊干预心衰大鼠心室重构作用机制研究》项目实施总结报告。项目编号2017122SF/YX016(1)。
作者单位邮编
谭毅 陕西中医药大学 712046
徐洋 陕西中医药大学 712046
赵中秋 陕西中医药大学 712046
刘鑫 陕西中医药大学 712046
刘畅 陕西中医药大学 712046
梁君昭* 西安市中医医院 710021
摘要点击次数: 27
全文下载次数: 0
中文摘要:
      目的:研究桂参通脉胶囊对心衰大鼠血管紧张素II(AngII)和醛固酮(ALD)的影响,探讨其在防治心力衰竭中的作用机制,为开发桂参通脉胶囊成为有效治疗心力衰竭的新药提供理论依据。方法:采用腹腔注射阿霉素溶液建立心力衰竭大鼠模型,随机将大鼠分为心衰模型组、桂参通脉胶囊高、中、低剂量组、卡托普利组及空白对照组,检测各组心衰大鼠血浆AngⅡ、ALD 水平及血清NT-proBNP 浓度差异,并观察心脏组织形态变化。结果:各组血浆 AngII、ALD 及血清NT-proBNP 浓度皆高于空白对照组,桂参通脉胶囊高、中剂量组和卡托普利组血浆 AngII、ALD 升高较少,桂参通脉胶囊高剂量组血清 NT-proBNP浓度最低;观测到各组均有不同程度心肌细胞凋亡,桂参通脉胶囊中、高剂量组和卡托普利组心肌细胞损伤较心衰模型组有明显改善,其光镜下病理评分差异有统计学意义(p<0.05)。结论:桂参通脉胶囊能够降低血浆 AngII、ALD 的水平,抑制神经内分泌系统的过度激活,延缓心室重构;降低血清 NT-proBNP,改善心功能;减少心肌细胞病理改变,减缓心肌细胞凋亡。
英文摘要:
      OBJECTIVE: To study the effects of Guishen Tongmai Capsule on angiotensin II (Ang II) and aldosterone (ALD) in rats with heart failure, and to explore its mechanism of action in the prevention and treatment of heart failure, and to effectively develop heart-to-heart treatment for Guishen Tongmai Capsule. The new drug for depletion provides a theoretical basis. METHODS: A rat model of heart failure was established by intraperitoneal injection of adriamycin solution. Rats were randomly divided into heart failure model group, Guishen Tongmai capsule high, medium and low dose groups, captopril group and blank control group. Plasma AngII, ALD levels and serum NT-proBNP concentrations were measured in each group of heart failure rats, and the changes of cardiac tissue morphology were observed. RESULTS: The plasma AngII, ALD and serum NT-proBNP concentrations in each group were higher than those in the blank control group. The plasma AngII and ALD levels were lower in the high- and medium-dose groups of the Guishen Tongmai capsule and the captopril group. The concentration of serum NT-proBNP was the lowest in the high-dose capsule group; the apoptosis of cardiomyocytes was observed in different groups. The myocardial cell damage in the middle and high dose groups of Guishen Tongmai Capsule and captopril group was significantly higher than that in the heart failure model group. The improvement was statistically significant (p<0.05). Conclusion: Guishen Tongmai Capsule can reduce the levels of plasma AngII and ALD, inhibit the excessive activation of neuroendocrine system and delay the ventricular remodeling; Guishen Tongmai Capsule can reduce serum NT-proBNP and improve cardiac function; Guishen Tongmai Capsule It can reduce the pathological changes of cardiomyocytes and slow down the apoptosis of cardiomyocytes.
View Fulltext   查看/发表评论  下载PDF阅读器
关闭
微信公众号
分享按钮